Table 3.
Clinical and laboratory features according to AQP4-AI status.
| AQP4-Ab AI pos | AQP4-Ab AI neg | |
|---|---|---|
| No of CSF samples | 1 | 22 |
| Sex | Female | All female |
| Age | 22 | 40 (14-72) |
| Diagnosis at time of LP | rON* | NMO in 11; LETM in 6; ON in 5 |
| IS/IM treatment at time of LP | Steroids until 5 d before LP | 11/22 |
| Disease duration in months, median | 19.4 | 20.5 (0.1-120) |
| Acute attack at time of LP | Yes | 19/22 |
| AQP4-Ab serum titre, median (range) | 1:1000 | 1000 (250-12500) |
| QIgG, median (range) | 5.85 | 4.8 (1.5-16.1) |
| Intrathecal synthesis of total IgG | Yes | 6/22 |
| QAlb, median (range) | 7.17 | 6.7 (3.2-31.1) |
| Blood-CSF barrier dysfunction | Yes | 11/22 |
* Developed NMO 10 months later. AI = antibody index; IS/IM = immunosuppressive/immunomodulatory; NMO = neuromyelitis optica; LETM = longitudinally extensive transverse myelitis; LP = lumbar puncture; QAlb = albumin CSF/serum ratio; QIgG = IgG CSF/serum ratio; rON = recurrent optic neuritis.